<SEC-DOCUMENT>0001104659-22-079524.txt : 20220713
<SEC-HEADER>0001104659-22-079524.hdr.sgml : 20220713
<ACCEPTANCE-DATETIME>20220713162236
ACCESSION NUMBER:		0001104659-22-079524
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220713
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220713
DATE AS OF CHANGE:		20220713

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Horizon Technology Finance Corp
		CENTRAL INDEX KEY:			0001487428
		IRS NUMBER:				272114934
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	814-00802
		FILM NUMBER:		221081272

	BUSINESS ADDRESS:	
		STREET 1:		312 FARMINGTON AVENUE
		CITY:			FARMINGTON
		STATE:			CT
		ZIP:			06032
		BUSINESS PHONE:		860-676-8654

	MAIL ADDRESS:	
		STREET 1:		312 FARMINGTON AVENUE
		CITY:			FARMINGTON
		STATE:			CT
		ZIP:			06032
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2220960d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):
July 13, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HORIZON TECHNOLOGY FINANCE CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>814-00802</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>27-2114934</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>312 Farmington Avenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Farmington, CT 06032</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <B>(860) 676-8654</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR &sect;240.12b-2). Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt">Ticker symbol(s)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">HRZN</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">4.875% Notes due 2026</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">HTFB</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">The New York Stock Exchange</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">6.25% Notes due 2027</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">HTFC</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">The New York Stock Exchange</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%"><FONT STYLE="font-size: 10pt"><B>Section 2</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Financial Information</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><B>Item 2.02</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Results of Operations and Financial Condition</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 13, 2022, Horizon Technology Finance Corporation
(the &#8220;Company&#8221;) issued a press release announcing its investment portfolio update for the three months ended June 30, 2022.
A copy of this press release is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in Item 2.02 of this Current Report
on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed &#8220;filed&#8221; for any purpose
of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to liabilities
of such Section. The information in this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%"><FONT STYLE="font-size: 10pt"><B>Section 9</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm2220960d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2220960d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press release of the Company dated July 13, 2022.&nbsp;&nbsp;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: July 13, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">HORIZON TECHNOLOGY FINANCE CORPORATION</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-size: 10pt">/s/ Robert D. Pomeroy, Jr.</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Robert D. Pomeroy, Jr. </FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2220960d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1<FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="tm2220960d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Horizon Technology Finance Provides Second Quarter
2022 Portfolio Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> - <I>Horizon Platform Originates Record $192 Million of New Loans in Q2, Including $137 Million of New Loans for HRZN - </I></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> - <I>Horizon Platform Ends Quarter with Record Committed Backlog of $267 Million, Including $221 Million in HRZN Commitments - </I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Farmington, Connecticut &ndash; July 13, 2022
&ndash; </B>Horizon Technology Finance Corporation (NASDAQ: HRZN) (&ldquo;HRZN&rdquo; or the &ldquo;Company&rdquo;), a leading specialty
finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science,
healthcare information and services, and sustainability industries, today provided its portfolio update for the second quarter ended June
30, 2022 and an update on the lending platform (&ldquo;Horizon Platform&rdquo;) of Horizon Technology Finance Management LLC (&ldquo;HTFM&rdquo;),
its investment adviser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;The Horizon Platform generated another
record-setting quarter of originations despite the challenging economic environment, closing $192 million of loans originated, including
$137 million of loans for HRZN,&rdquo; said Gerald A. Michaud, President of HRZN and HTFM. &ldquo;In addition, the Horizon brand continues
to attract state-of-the-art companies, as the Horizon Platform&rsquo;s committed backlog grew to a record $267 million of debt investments,
including $221 million in HRZN commitments. HRZN also received $57 million in loan prepayments during the quarter, providing additional
income and further validating our predictive pricing strategy. There remains a clear need and demand for venture debt in this economic
environment, and we believe the Horizon Platform and HRZN remain disciplined and well positioned to further grow and deliver additional
value to HRZN&rsquo;s shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Second Quarter 2022 Portfolio Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Originations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2022, a total of
$192.4 million of loans funded through the Horizon Platform, including 15 loans totaling $137.2 million funded by HRZN as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$26.0 million to an existing portfolio company,
Castle Creek Biosciences, Inc., a developer of gene therapies for patients with rare and serious genetic diseases, in connection with
the prepayment of its existing Horizon Platform loan facility and providing it with additional debt capital.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext">$15.0 million to a new portfolio
company, Divergent Technologies Inc., </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">a creator of an innovative global
manufacturing infrastructure platform for the automotive industry.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$12.5 million to a new portfolio company, a clinical-stage
company focused on decoding the entire genome to identify optimal gene targets to cure oncology and autoimmune diseases. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$12.5 million to an existing portfolio company,
NextCar Holding Company, Inc. (dba Autonomy), an online platform offering automobiles to consumers on a subscription basis. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$10.0 million to a new portfolio company, a developer
of a breathalyzer test to detect recent cannabis use.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$10.0 million to an existing portfolio company,
IMV Inc. (NASDAQ: IMV), a clinical-stage biopharmaceutical company developing a new class of cancer immunotherapies and infectious disease
vaccines. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$10.0 million to an existing portfolio company,
Nexii Building Solutions Inc., a green construction company that designs and manufactures low carbon buildings and products. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$7.5 million to a new portfolio company, Engage3,
LLC, a developer of price optimization software that enables retailers and brands to profitably grow revenue and drive additional store
trips.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2220960d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$7.5 million to a new portfolio company, a developer
of innovative medical devices and therapies to address the evolving needs of interventional specialists.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$7.5 million to an existing portfolio company,
Soli Organic Inc., a leading grower and marketer of fresh organic culinary herbs, providing sustainable, USDA-certified organic, regionally
grown produce to retailers.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$7.0 million to a new portfolio company, Swift
Health Systems, Inc. (dba InBrace), a developer of teeth straightening technology that provides an alternative to traditional braces and
aligners.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$5.0 million to an existing portfolio company,
Emalex Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement
disorders and fluency disorders.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$3.75 million to a new portfolio company, a developer of next generation microbial solutions for both companion and livestock animals.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext">$2.5 million to an existing
portfolio company,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Secure Transfusion Services, Inc., an operator of commercial
blood collection centers that source and distribute vital, in-demand blood components to hospitals.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$0.4 million to an existing company, MacuLogix,
Inc., a medical device company in the optometry and ophthalmology industry.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity Events </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HRZN experienced liquidity events from four portfolio
companies in the second quarter of 2022, including principal prepayments of $56.8 million and $0.4 million of warrant and earnout proceeds,
compared to $12.0 million of principal prepayments during the first quarter of 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In April, with the proceeds of a new loan from
the Horizon Platform, Castle Creek Biosciences, Inc. prepaid its previously outstanding principal balance of $25.0 million on its venture
loan facility, plus interest and end-of-term payment. HRZN continues to hold warrants in the company.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In May, Updater, Inc. prepaid its outstanding
principal balance of $19.3 million on its venture loan, plus interest, end-of-term payment and prepayment fee. HRZN continues to hold
warrants in the company. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In June, IDbyDNA, Inc. was acquired by Illumina,
Inc. and prepaid its outstanding principal balance of $12.5 million on its venture loan, plus interest, end-of-term payment and prepayment
fee. <FONT STYLE="color: windowtext">HRZN also received proceeds totaling $0.3 million from the redemption of warrants it held in the
company.&nbsp;</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In June, HRZN earned a $0.1 million earnout payment
related to its investment in Bardy Diagnostics, Inc.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Principal Payments Received</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2022, HRZN received
regularly scheduled principal payments on investments totaling $4.0 million, compared to regularly scheduled principal payments totaling
$1.9 million during the first quarter of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Commitments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarter ended June 30, 2022, HRZN closed
new loan commitments totaling $203.4 million to 10 companies, compared to new loan commitments of $100.4 million to 11 companies in the
first quarter of 2022. HTFM&rsquo;s other managed funds, during the quarter, closed new loan commitments totaling $80.0 million of unfunded
loan approvals and commitments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2220960d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pipeline and Term Sheets </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, HRZN&rsquo;s unfunded loan
approvals and commitments (&ldquo;Committed Backlog&rdquo;) were $220.5 million to 23 companies. This compares to a Committed Backlog
of $150.8 million to 20 companies as of March 31, 2022. HRZN&rsquo;s portfolio companies have discretion whether to draw down such commitments
and the right of a portfolio company to draw down its commitment is often subject to achievement of specific milestones and other conditions
to borrowing. Accordingly, there is no assurance that any or all of these transactions will be funded by HRZN. HTFM&rsquo;s other managed
funds ended the quarter with a total of $46.5 million of unfunded loan approvals and commitments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarter, HTFM received signed term
sheets that are in the approval process, which may result in the Horizon Platform providing up to an aggregate of $165.0 million of new
debt investments. These opportunities are subject to underwriting conditions including, but not limited to, the completion of due diligence,
negotiation of definitive documentation and investment committee approval, as well as compliance with HTFM&rsquo;s allocation policy.
Accordingly, there is no assurance that any or all of these transactions will be completed or funded by HRZN.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrant and Equity Portfolio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, HRZN held a portfolio of
warrant and equity positions in 90 portfolio companies, including 76 private companies, which provides the potential for future additional
returns to HRZN&rsquo;s shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Horizon Technology Finance </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Horizon Technology Finance Corporation (NASDAQ:
HRZN) is a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in
the technology, life science, healthcare information and services, and sustainability industries. The investment objective of HRZN is
to maximize its investment portfolio&rsquo;s return by generating current income from the debt investments it makes and capital appreciation
from the warrants it receives when making such debt investments. Horizon Technology Finance Management LLC is headquartered in Farmington,
Connecticut, with a regional office in Pleasanton, California, and investment professionals located in Portland, Maine, Austin, Texas,
and Reston, Virginia. To learn more, please visit <U>www.horizontechfinance.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Statements included herein may constitute
&quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than
statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future
performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in
the forward-looking statements as a result of a number of factors, including those described from time to time in Horizon&rsquo;s filings
with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking
statements speak only as of the date of this press release.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><IMG SRC="tm2220960d1_ex99-1img01.jpg" ALT="">&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ICR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Garrett Edson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>ir@horizontechfinance.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(860) 284-6450</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Media Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ICR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chris Gillick</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>HorizonPR@icrinc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(646) 677-1819</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2220960d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2220960d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !( 2P# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^M3_@H_\
MMRZO^PA\-?A[\0-'^&^G?$B3QI\1&\$2Z7J7B6\\-1V"'PKKGB$:BMQ!HVM&
MYE#Z+Y2Q.(!M?>'+#"?D!_Q$3>-CU_95\*[AZ_%75"3D>W@P\\#/&>,GH:^D
M?^#AG!_9Q^ XYS_PT$ /3_DF'CXYZ@_E[U_)<#D@\$G  YR3E?N* S,5#%V5
M0QVHS@?+7[1P-PED&=9!A\PS'!?6,14JSBZ<ISC"48R=E/EG%<MMWW2/P'Q
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M@2WA+Z=,D?UO\/OVG/$_]I?&2R_:3^'&B_LR:1\*_$WA+1-&\=^+?B9H%_\
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M_$UJNN";0];N[R*XL4LM3DM99[RUE@MK4R!PH![%17 1?$_X>36&DZI%\0O
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MINJR7-W^M?PYT;X%_#+_ (+O^$K+X$^%_"G@/PG\2?\ @F ^B>*IOAWX,O\
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ML58BC0QIY8B\F4F %T8JVR**-@N& 4*I /Y#K?X5> /V/O$__!&2_P#$^O\
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6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
